Clinicopathological characteristics and survival outcomes of early-onset vs mid-aged gastric cancer using an evidence-based age cutoff

Figure 1  Study flow diagram.

Figure 2 Kaplan-Meier curves for overall survival and recurrence-free survival in the overall study populations after inverse probability of treatment weighting. A: Five-year recurrence-free survival was 81.36% in the early-onset gastric cancer (EOGC) group and 72.10% in the mid-aged gastric cancer (M-GC) group [hazard ratio (HR), 0.59; log-rank P = 0.021]; B: Five-year overall survival was higher in the EOGC group (81.00% vs 75.71% in the M-GC group; HR, 0.58; log-rank P = 0.016). HR: Hazard ratio; CI: Confidence interval; M-GC: Mid-aged gastric cancer; EOGC: Early-onset gastric cancer.

Figure 3 Kaplan-Meier curves for recurrence-free survival by pathological stage after inverse probability of treatment weighting. A: Stage I: 5-year recurrence-free survival (RFS), 93.77% vs 88.66% in early-onset gastric cancer(EOGC) and mid-aged gastric cancer (M-GC), respectively (P = 0.234); B: Stage II: 5-year RFS, 80.55% vs 64.75% in EOGC and M-GC, respectively (P = 0.136); C: Stage III: 5-year RFS in stage III, 57.62% vs 36.14% in EOGC and M-GC, respectively (P = 0.032). M-GC: Mid-aged gastric cancer; EOGC: Early-onset gastric cancer.

Figure 4 Kaplan-Meier curves for overall survival by pathological stage after inverse probability of treatment weighting. A: Stage I: 5-year overall survival (OS), 93.74% vs 92.19% in early-onset gastric cancer (EOGC) and mid-aged gastric cancer (M-GC), respectively (P = 0.056); B: Stage II: 5-year OS, 84.86% vs 77.62% in EOGC and M-GC, respectively (P = 0.225); C: Stage III: 5-year OS, 60.86% vs 43.75% in EOGC and M-GC, respectively (P = 0.120); D: Stage IV: 5-year OS, 14.29% vs 5.56% in EOGC and M-GC, respectively (P = 0.052). M-GC: Mid-aged gastric cancer; EOGC: Early-onset gastric cancer.